Skip to main content
Erschienen in: Supportive Care in Cancer 12/2020

04.07.2020 | Review Article

Transdermal versus oral granisetron in controlling chemotherapy-induced nausea and vomiting: a meta-analysis

verfasst von: Alfredo V. Chua Jr., Aylmer Rex B. Hernandez, Irisyl O. Real

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare the efficacy of transdermal granisetron versus oral granisetron in controlling chemotherapy-induced nausea and vomiting (CINV) in patients with cancer

Methods

Data sources were CENTRAL, MEDLINE, EMBASE, Clinicaltrials.​gov, and Google Scholar. Inclusion criteria included randomized controlled trials comparing transdermal versus oral granisetron in patients with CINV. For data extraction, two authors independently analyzed the methodological quality and extracted data. A random effects model was used to estimate the risk ratio (RR) or odds ratio (OR) with 95% confidence interval (CI).

Results

Three studies (1086 patients) were included. Oral granisetron is superior (OR 0.77; 95% CI 0.60 to 0.99) to its transdermal form in achieving complete control of CINV in patients receiving chemotherapy. As for the risk of constipation (RR 1.32; 95% CI 0.73 to 2.40) and QTc prolongation (RR 0.17; 95% CI 0.02 to 1.40) as adverse effects, no statistically significant difference was observed between the two routes.

Conclusion

Oral granisetron is better in achieving complete control of CINV in patients receiving chemotherapy. As for the risk of constipation and QTc prolongation as adverse effects, there was no statistically significant difference between the two routes.
Literatur
1.
Zurück zum Zitat Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM, Sancuso Study Group (2011) Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 19:1609–1617CrossRef Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM, Sancuso Study Group (2011) Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 19:1609–1617CrossRef
2.
Zurück zum Zitat Kim JE, Hong YS, Lee JL, Kim KP, Park SJ, Sym SJ, Shin DB, Lee J, Park YS, Ahn JS, Kim TW (2015) A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. Support Care Cancer 23:1769–1777CrossRef Kim JE, Hong YS, Lee JL, Kim KP, Park SJ, Sym SJ, Shin DB, Lee J, Park YS, Ahn JS, Kim TW (2015) A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. Support Care Cancer 23:1769–1777CrossRef
3.
Zurück zum Zitat Duggan ST, Curran MP (2009) Transdermal granisetron. Drugs. 69(18):2597–2605CrossRef Duggan ST, Curran MP (2009) Transdermal granisetron. Drugs. 69(18):2597–2605CrossRef
4.
Zurück zum Zitat Schell FM (2003) Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist. 8:187–198CrossRef Schell FM (2003) Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist. 8:187–198CrossRef
5.
Zurück zum Zitat Frame DG (2010) Best practice management of CINV in oncology patients: I. physiology and treatment of CINV-multiple neurotransmitters and receptors and the need for combination therapeutic approaches. J Support Oncol 8(suppl 1):5–9PubMed Frame DG (2010) Best practice management of CINV in oncology patients: I. physiology and treatment of CINV-multiple neurotransmitters and receptors and the need for combination therapeutic approaches. J Support Oncol 8(suppl 1):5–9PubMed
6.
Zurück zum Zitat Coluzzi F, Mattia C (2016) Management of chemotherapy-induced nausea and vomiting in patients receiving multi-day highly or moderately emetogenic chemotherapy: role of transdermal granisetron. Future Oncol 12(16):1856–1876CrossRef Coluzzi F, Mattia C (2016) Management of chemotherapy-induced nausea and vomiting in patients receiving multi-day highly or moderately emetogenic chemotherapy: role of transdermal granisetron. Future Oncol 12(16):1856–1876CrossRef
7.
Zurück zum Zitat Yang LQ, Sun XC, Qin SK, Chen YX, Zhang HL, Cheng Y, Chen ZD, Shi JH, Wu Q, Bai YX, Han BH, Liu W, Ouyang XN, Liu JW, Zhang ZH, Li YQ, Xu JM, Yu SY (2016) Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study. Chin Clin Oncol 5(6):79CrossRef Yang LQ, Sun XC, Qin SK, Chen YX, Zhang HL, Cheng Y, Chen ZD, Shi JH, Wu Q, Bai YX, Han BH, Liu W, Ouyang XN, Liu JW, Zhang ZH, Li YQ, Xu JM, Yu SY (2016) Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study. Chin Clin Oncol 5(6):79CrossRef
8.
Zurück zum Zitat Roila F, Hesketh PJ, Herrstedt J, Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17(1):20CrossRef Roila F, Hesketh PJ, Herrstedt J, Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17(1):20CrossRef
9.
Zurück zum Zitat Mason JW, Selmess DS, Moon TE, O’Mahony B, Donachie P, Howell J (2012) Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron. Clin Cancer Res 18(10):2913–2921CrossRef Mason JW, Selmess DS, Moon TE, O’Mahony B, Donachie P, Howell J (2012) Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron. Clin Cancer Res 18(10):2913–2921CrossRef
10.
Zurück zum Zitat Al Harbi M, Al Rifai D, Al Habeeb H, Wambi F, Geldhof G, Dimitiou V (2016) A case of granisetron associated intraoperative cardiac arrest. Middle East J Anesthesiol 23(4):475–478PubMed Al Harbi M, Al Rifai D, Al Habeeb H, Wambi F, Geldhof G, Dimitiou V (2016) A case of granisetron associated intraoperative cardiac arrest. Middle East J Anesthesiol 23(4):475–478PubMed
11.
Zurück zum Zitat Mason JW, Moon TE, O’Boyle EO, Dietz A (2014) A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation. Cancer Manag Res 6:181–190CrossRef Mason JW, Moon TE, O’Boyle EO, Dietz A (2014) A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation. Cancer Manag Res 6:181–190CrossRef
12.
13.
Zurück zum Zitat Tuca A (2010) Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review. Cancer Manag Res 2:1–12 Tuca A (2010) Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review. Cancer Manag Res 2:1–12
Metadaten
Titel
Transdermal versus oral granisetron in controlling chemotherapy-induced nausea and vomiting: a meta-analysis
verfasst von
Alfredo V. Chua Jr.
Aylmer Rex B. Hernandez
Irisyl O. Real
Publikationsdatum
04.07.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 12/2020
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-020-05611-w

Weitere Artikel der Ausgabe 12/2020

Supportive Care in Cancer 12/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.